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Abstract
Background: Endpoint adjudication committees (EPAC) are widely used in clinical trials. The aim of the present analysis is to
assess the effects of the endpoint adjudication process on the main findings of the ADVANCE trial (Trial registration:
ClinicalTrials.gov NCT00145925).
Methods and Findings: The ADVANCE trial was a multicentre, 262 factorial randomised controlled trial of blood pressure
lowering and intensive blood glucose control in 11140 patients with type 2 diabetes. Primary outcomes were major
macrovascular (nonfatal myocardial infarction, nonfatal stroke and cardiovascular death) and microvascular (new or
worsening nephropathy and retinopathy) events. Suspected primary outcomes were initially reported by the investigators
at the 215 sites with subsequent adjudication by the EPAC. The EPAC also adjudicated upon potential events identified
directly by ongoing screening of all reported events. Over a median follow-up of 5 years, the site investigators reported one
or more primary outcomes among 2443 participants. After adjudication these events were confirmed for 2077 (85%) with 48
further events added through the EPAC-led database screening process. The estimated relative risk reductions (95%
confidence intervals) in the primary outcome for the blood pressure lowering comparison were 8% (21 to 15%) based on
the investigator-reported events and 9% (0 to 17%) based on the EPAC-based events (P for homogeneity = 0.70). The
corresponding findings for the glucose comparison were 8% (1 to 15%) and 10% (2% to 18%) (P for homogeneity = 0.60).
The effect estimates were also highly comparable when studied separately for macrovascular events and microvascular
events for both comparisons (all P for homogeneity.0.6).
Conclusions: The endpoint adjudication process had no discernible impact on the main findings in ADVANCE. These data
highlight the need for careful consideration of the likely impact of an EPAC on the findings and conclusions of clinical trials
prior to their establishment.
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Introduction
Much attention is given to the diagnosis of outcomes in large-
scale multicentre trials because achieving consistency of reporting
is perceived as a major challenge [2]. Standardized definitions of
outcomes and protocols for their assignment are routinely used,
but the possibility of misclassification remains. Accordingly, the
design of most recent large-scale trials has included an endpoint
adjudication committee (EPAC) that is blinded to study treatments
and is responsible for assuring the validity of diagnoses for main
trial outcomes [3–11]. However, it remains uncertain whether the
endpoint adjudication process really improves the precision and
validity of the treatment effects reported.
The Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled Evaluation (ADVANCE)
trial (Trial registration: ClinicalTrials.gov NCT00145925) was a
multicentre, 2x2 factorial randomised controlled trial in patients
with type 2 diabetes, which demonstrated separately beneficial
effects of blood pressure lowering and intensive blood glucose
control on the development of major macrovascular and
microvascular diseases [1,12,13]. The aim of the present analysis
is to assess the impact of the endpoint adjudication process on the
main findings of the ADVANCE trial.
Methods
Ethics statement
Approval for the ADVANCE trial was obtained from each
centre’s institutional review board, and all participants provided
written informed consent. A full list of 215 centres that
participated in the trial was published previously [1].
Design of the ADVANCE trial
The design of the ADVANCE trial has been described in detail
previously [1,12,13], and the CONSORT checklist is available as
Supporting Information, see Checklist S1. In brief, a total of 11140
patients with type 2 diabetes aged $55 years, with a history of
major macrovascular or microvascular disease or at least one other
risk factor for vascular disease, were enrolled from 215 centres in
20 countries between June 2001 and March 2003. After a 6-week
active run-in period with fixed-combination of perindopril and
indapamide during which usual glucose control was continued,
participants were randomly assigned, in a 2x2 factorial design, to
continued perindopril-indapamide or matching placebo and to
either a gliclazide MR based intensive glucose control strategy
aiming for a haemoglobin A1c of #6.5% or a standard glucose
control strategy. Study treatments were allocated using a central,
computer-based, randomisation service accessible by internet,
telephone, and facsimile. Randomisation was stratified by study
centre, history of macrovascular disease, history of microvascular
disease, and background use of perindopril at baseline. All
participants were allocated to one of the two randomised groups
for both the blood pressure and the blood glucose interventions.
The blood pressure lowering intervention was a placebo-controlled
double-blind design, in which site investigators, patients and
endpoint adjudicators were all blinded to randomised treatment
allocation. The blood glucose control intervention was a prospec-
tive randomised open blinded endpoint (PROBE) design, in which
site investigators and patients were not blinded but all endpoint
adjudicators were blinded. Median treatment follow-up was 4.3
years for the blood pressure lowering arm of the trial, and 5 years
for the glucose control intervention (Figure 1).
Definitions of study outcomes
The primary outcomes of the ADVANCE trial were a
composite of major macrovascular events (nonfatal myocardial
infarction, nonfatal stroke, or cardiovascular death) and a
composite of major microvascular events (new or worsening
nephropathy or retinopathy), considered both jointly and sepa-
rately. Myocardial infarction was defined as the presence of any
two of the following three criteria; (1) a history of typical ischaemic
symptoms lasting for $15 minutes and unresponsive to sublingual
nitrates (if given), (2) diagnostic electrocardiogram changes (e.g. ST
segment elevation/depression, new pathological Q wave), and (3)
raised biochemical markers of myocardial damage (e.g. creatine
kinase, troponin T); or autopsy findings of acute myocardial
infarction (International Classification of Diseases 10th Revision
[ICD-10] codes of I21.0-I21.9, I22.0-I22.9). Stroke was defined as
a clinical history of acute disturbance of focal neurological function
resulting in symptoms lasting .24 hours and thought to be due to
brain infarction or intracranial haemorrhage (ICD-10 codes of
I61.0-I61.9, I62.1, I62.9, I63.0-I63.9, I64) supported by brain
imaging or autopsy. Subarachnoid haemorrhage, subdural haem-
orrhage and transient ischaemic attack were not included in the
definition of stroke. Nonfatal myocardial infarction or nonfatal
stroke was defined as an event that did not result in death within
28 days from onset. Cardiovascular death was defined as any
death in which the proximate or the underlying cause of death was
due to a disease of the circulatory system (ICD-10 codes of I10-
I14, I20-I25, I26, I27.9, I28, I50-I52, I60-I67, I69, I70-I79, I80-
I89) or a sudden death (ICD-10 codes of R96.0, R96.1, I46.1,
R98). New or worsening nephropathy was defined as development
of macroalbuminuria (a urinary albumin to creatinine ratio
.300 mg/mg) confirmed by two positive results, doubling of the
serum creatinine to a level of at least 200 mmol/L, the need for
renal replacement therapy (dialysis or transplantation), or death
from renal disease (ICD-10 codes of N00-N29, E11.2, I12, I13).
New or worsening retinopathy was defined as development of
proliferative retinopathy, macular oedema or diabetes-related
blindness, or the use of retinal photocoagulation therapy. A
secondary outcome, also included in the present analysis, was
death from any cause.
Event reporting by the site investigators
The site investigators were a diverse group of physicians with
different levels of experience trained in many different countries.
Serious events recorded in the trial (including all suspected
primary and secondary outcomes) were identified and first
reported by one of the local site investigators using a standard
‘‘serious event form’’ accompanied by specified supporting
documents. These outcomes were all assigned an ICD-10 or
study-specific code (for those without applicable ICD-10 codes) by
the clinical coordinator of the ADVANCE trial on the basis of the
site investigators’ diagnoses.
Event reporting by the EPAC
All possible primary outcomes and deaths (both cardiovascular
and noncardiovascular) were reviewed by the EPAC whose
members (comprising cardiologists, neurologists, endocrinologists,
nephrologists and ophthalmologists) were blinded to randomised
treatment assignments. Using the supporting documents (e.g.
electrocardiogram findings, laboratory test reports, findings of
brain computed tomography or magnetic resonance imaging,
clinical notes, ophthalmology reports, autopsy reports and death
certificates), which had been translated as necessary, the EPAC
either confirmed or refuted the initial diagnosis reported by the site
investigators using standardized definitions and protocol. When
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the initial diagnosis made by the site investigator was refuted, an
alternative diagnosis was provided and an ICD-10 or study-
specific code assigned. In addition, throughout the trial we
conducted central searches of all information collected on serious
events and follow-up assessments, to identify possible primary
outcomes that might have been incorrectly or incompletely
reported by the site investigators. For these potential additional
events supporting data were sought from the site investigators and
then reviewed by the EPAC in the same way. Consequently, the
EPAC identified misclassification in the site investigators’ diagnosis
(e.g. misclassification between myocardial infarction and stroke,
misclassification between fatal and nonfatal myocardial infarction
or stroke, incorrect causes of death). The EPAC also reviewed
incomplete or unclassified events (e.g. unspecified cardiovascular
disease, death of unknown cause) and determined whether these
events met the definition of each outcome or not. In addition,
laboratory data such as serum creatinine and urine albumin/
creatinine ratio in the follow-up assessments were reviewed to
identify possible unreported nephropathy events. Consequently, 3
events of nonfatal myocardial infarction, 4 of nonfatal stroke, and
10 of new or worsening nephropathy which were unreported or
misclassified by the site investigators, were included into the
outcomes by the EPAC. The EPAC also added 95 cardiovascular
death events from the patients who were classified as death from
non-cardiovascular or unknown causes by site investigators
(Table 1).
Statistical methods
The impact of the endpoint adjudication process on the main
results of the ADVANCE trial was estimated by calculating the
treatment effects on the outcomes of interest using univariate Cox
proportional hazards models. The models were first fitted using
the dataset based on the site investigators’ initial diagnoses and
second using the dataset based on the EPAC final diagnoses. For
composite outcomes and patients with multiple events, the first
applicable event was used in each analysis. All analyses were done
according to the principle of intention to treat with relative risk
reductions reported as percentage reductions ([1 - hazard ratio]
Figure 1. Enrolment, randomisation, and follow-up of study participants. A total of 11140 patients were randomly assigned, in a 2x2
factorial design, to active blood pressure lowering treatment with perindopril-indapamide or matching placebo, and to a gliclazide-based intensive
glucose control strategy or a standard glucose control strategy.
doi:10.1371/journal.pone.0055807.g001
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6100). The homogeneity between the treatment effects estimated
using the site investigators’ diagnoses and the EPAC diagnoses was
addressed through a test of the null hypothesis that the EPAC
hazard ratio was equal to the investigators hazard ratio for each
outcome [3]. This test exploits the sequential nature of the
diagnostic process; the EPAC diagnosis was made in the
knowledge of the investigators’ diagnosis. In addition, we
estimated the percentage of error saved by the endpoint
adjudication process through a comparison of mean square errors
(MSEs) [3]. Assuming that the effect estimate based on the EPAC
diagnoses is unbiased, the percentage of error saved by the
endpoint adjudication process was estimated as = {(!MSE[i] -
!MSE[e])/!MSE[i]}6100, where MSE[e] is the variance of the
log hazard ratio based on the EPAC diagnoses and MSE[i] is the
variance of the log hazard ratio based on the investigators’
diagnoses plus the squared difference between the log hazard ratio
estimate based on the investigators’ and the EPAC diagnoses. The
bias-corrected and accelerated mean and 95% confidence interval
(CI) of the percentage of error saved by the endpoint adjudication
process (which had a skewed distribution) was estimated from
10,000 bootstrap samples. All analyses were performed using SAS
9.2 (SAS Institute, Cary, North Carolina, USA).
Results
Comparison of diagnoses made by site investigators and
the EPAC
Over a median follow-up of 5 years, the site investigators
reported one or more primary macrovascular or microvascular
outcome for 2443 participants. After adjudication these events
were confirmed for 2077 (85%) with 48 further events added
through the database screening process (Table 1). The numbers of
events initially reported by the site investigators and finally
diagnosed by the EPAC were 1310 and 1147 for major
macrovascular events, 1357 and 1131 for major microvascular
events, and 1031 and 1031 for death from any cause, respectively.
The proportion of the investigator-reported events confirmed by
the EPAC was greater than 70% for all the composite primary
outcomes and their major components.
Impact of endpoint adjudication on the effect estimates
for blood pressure lowering comparison
Figure 2 demonstrates the effects of blood pressure lowering
treatment on the relative risk reductions of outcomes based on the
initial diagnoses made by the site investigators and those based on
the final diagnoses of the EPAC. Perindopril/indapamide-based
blood pressure lowering treatment reduced the risk of combined
macrovascular and microvascular events based on the investiga-
tors’ diagnoses by 8% (95% CI -1 to 15%) and those based on the
EPAC diagnoses by 9% (95% CI 0 to 17%) (P=0.70 for
homogeneity). Estimates of treatment effect based on the
investigators’ diagnoses and the EPAC diagnoses were highly
comparable for every other outcome reported for this comparison
(all P for homogeneity.0.6). In addition the estimated percent
error saved by the adjudication process was small in every case.
Impact of endpoint adjudication on the effect estimates
for the glucose comparison
The effects of intensive glucose control on relative risks are
shown in Figure 3. There were comparable reductions in the
relative risks of combined macrovascular and microvascular events
based on the investigators’ diagnoses (8%, 95% CI 1 to 15%) and
on the EPAC diagnoses (10%, 95% CI 2 to 18%) (P for
homogeneity = 0.60). Likewise, there was no difference in
estimates of treatment effect based on the investigators’ diagnoses
and the EPAC diagnoses for every other outcome (all P for
homogeneity.0.7) and the percent error saved by the adjudica-
tion process was again minimal in every case.
Discussion
In the present analysis, the endpoint adjudication process
moved the point estimates of relative risk reductions in the blood
pressure arm slightly to the left (more favourable in the active
group) for 4 outcomes, slightly to the right (less favourable) for 3
outcomes, and left the estimate unchanged for 2 outcomes. The
corresponding 95% CIs were made slightly wider by adjudication
for 7 outcomes, slightly narrower for 1 outcome and were
unchanged for 1 outcome. In the glucose arm, point estimates
were moved slightly to the left for 3 outcomes, slightly to the right
for 3 outcomes, and unchanged for 3 outcomes; and 95% CIs were
made slightly wider for 7 outcomes, slightly narrower for 1
Table 1. Number of events reported by the site investigators (SI) and confirmed, declined or added by the endpoint adjudication
committee (EPAC) over a median follow-up of 5 years.
Outcome
Reported by
SI
Confirmed by
EPAC*
Declined by
EPAC*
Added by
EPAC{
Diagnosed by
EPAC
Combined major macrovascular and microvascular events 2443 2077 (85.0%) 366 (15.0%) 48 (2.3%) 2125
Major macrovascular events 1310 1098 (83.8%) 212 (16.2%) 49 (4.3%) 1147
Nonfatal myocardial infarction 399 306 (76.7%) 93 (23.3%) 3 (1.0%) 309
Nonfatal stroke 576 419 (72.7%) 157 (27.3%) 4 (0.9%) 423
Cardiovascular death 487 447 (91.8%) 40 (8.2%) 95 (17.5%) 542
Major microvascular events 1357 1122 (82.7%) 235 (17.3%) 9 (0.8%) 1131
New or worsening nephropathy 606 512 (84.5%) 94 (15.5%) 10 (1.9%) 522
New or worsening retinopathy 852 681 (79.9%) 171 (20.1%) 0 (0.0%) 681
Death from any cause 1031 1031 (100.0%) 0 (0.0%) 0 (0.0%) 1031
*Number and percentage among the events originally reported by SI.
{Number and percentage among the events finally diagnosed by EPAC.
doi:10.1371/journal.pone.0055807.t001
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outcome and were unchanged for 1 outcome. For none of the
analyses were the estimates based on the adjudicated outcomes
shown to be substantially different from the estimates made using
the original diagnoses reported by the investigators, and in every
case the ‘error saved’ through the adjudication process was small.
Our findings raise some uncertainty about the purely scientific
value of the endpoint adjudication process in large-scale
randomised controlled trials with characteristics similar to those
of the ADVANCE trial, though as discussed below this may vary
with trial design. On the other hand, the adjudication process does
provide reassurance to users of the trial results including health
funders and regulators. While the scientific value of endpoint
adjudication in large-scale randomised controlled trials may be
debatable, it is clear that it will remain an essential element for trial
design as long as regulatory agencies insist upon it before
approving new treatments or devices.
Multicentre trials are clearly at risk of outcome misclassification
caused by differential application of definitions by site investiga-
tors. Three factors seem to be associated with the risk of
misclassification and the necessity of adjudication processes;
namely the nature of outcomes, the quality of site investigators
and the study design.
The nature of the outcomes is a primary factor which is
associated with the risk of misclassification. This risk can be
minimized by adopting ‘hard outcomes’ with clear and objective
definitions. We recently reported that the misclassification of
outcomes in the Perindopril Protection Against Recurrent Stroke
Study (PROGRESS) (i.e. stroke, myocardial infarction and cause-
specific death) is infrequent and that the EPAC had little impact
on treatment effects [3]. A recent systematic review of investigator
and EPAC diagnoses showed good inter-observer agreement for
reporting of macrovascular outcomes of this type [4]. In the
Figure 2. Effects of endpoint adjudication on the results of ADVANCE blood pressure lowering arm. Effects of blood pressure lowering
treatment on the risks of clinical outcomes were examined based on diagnoses reported by the site investigators (SI) and those assigned by the
endpoint adjudication committee (EPAC). Centers of the boxes are placed at the estimates of effect; areas of the boxes are proportional to the
reciprocal of the variance of the estimates. Horizontal lines represent 95% confidence intervals (CI).
doi:10.1371/journal.pone.0055807.g002
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present study, we reconfirmed similar results for macrovascular
outcomes and death. In addition, the present study is the first
report to confirm the lack of significant influence of the
adjudication process on the estimates of microvascular complica-
tions in diabetes. The macrovascular and microvascular events
that formed the primary outcome in ADVANCE are fairly easy to
diagnose correctly and death is the least likely event to be
misreported. On the other hand, there will be some circumstances
in which adjudication is required. For example, in the Platelet
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression
Using Integrilin Therapy (PURSUIT) trial, in patients with acute
coronary syndromes (ACS), importantly different estimates of
treatment effects have been reported based on adjudicated and
unadjudicated diagnoses of myocardial infarction [5,6]. Although
myocardial infarction is usually considered to be a hard outcome
and easy to diagnose (as in the ADVANCE trial), the accurate
diagnosis of myocardial infarction may be more difficult in specific
circumstances, such as the acute setting of ACS in the PURSUIT
trial. Thus, in studies using ‘soft outcomes’ which are difficult to
diagnose objectively or derived from less reliable sources, the
adjudication process may exert a significant impact on the study
conclusions.
The quality of site investigators may be also an important factor.
In ADVANCE, the sites involved were centres of excellence in
their respective countries with leadership by senior physicians in
the field. Large scale clinical trials have rigorous site selection
processes and it may well be that careful site selection is able to
provide similar degrees of assurance of reliable outcome reporting
to that obtained through a separate endpoint adjudication process.
Study design is possibly the most important determinant of the
necessity for an independent endpoint adjudication process. Even
if hard outcomes and careful site selection do apply, it is impossible
Figure 3. Effects of endpoint adjudication on the results of ADVANCE blood glucose control arm. Effects of intensive glucose control on
the risks of clinical outcomes were examined based on diagnoses reported by the site investigators (SI) and those assigned by the endpoint
adjudication committee (EPAC). Centers of the boxes are placed at the estimates of effect; areas of the boxes are proportional to the reciprocal of the
variance of the estimates. Horizontal lines represent 95% confidence intervals (CI).
doi:10.1371/journal.pone.0055807.g003
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to eradicate outcome misclassification completely. However, this
need not be a major issue provided rigorous randomization is
used, thus ensuring that the risks of misclassification are
nondifferential between the treatment groups to be compared.
Such nondifferential misclassification can be achieved in double-
blinded randomised trials (e.g. blood pressure arm in ADVANCE)
in which site investigators report events without any knowledge of
study treatments. If the misclassification is infrequent and
nondifferential, adjudication processes may have little impact on
point estimates of treatment effect. The risks of differential
misclassification are theoretically greater in open-label trials,
where site investigators may have preconceived notions about
the treatment effect and may report outcome-related events
differentially between the treatment groups. Even here however,
these risks may be minimized through use of a PROBE design
with reliance on a blinded adjudication process, as was used in the
glucose arm of ADVANCE. An adjudication process may also be
important for observational studies in which differential misclas-
sification between the study groups may be more likely.
In the present analysis in ADVANCE, the systematic slight
widening of the CIs in relative risks in both treatment arms was
attributable to the EPAC discarding a small number of the events
originally reported by the site investigators. There was no evidence
of bias in the point estimates of treatment effect based on
unadjudicated outcomes. Therefore, it would appear that the
primary impact of the adjudication process was to slightly reduce
the statistical power.
Endpoint adjudication in the ADVANCE trial consumed very
considerable resources and, although a formal estimate of cost was
not possible, likely required more than a million dollars. These
resources were mostly expended on the collection of additional
data from sites, translation of documents, payment of the
adjudicators and central coordination including the establishment
of a dedicated database and tracking tool. With clinical research
costs escalating, it is the responsibility of researchers to ensure that
scarce resources are applied as sparingly and as efficiently as
possible.
In conclusion, the endpoint adjudication process used in the
ADVANCE trial had no discernible effect on the main findings of
the trial in regard to either macrovascular or microvascular
outcomes. These data highlight the need for careful consideration
of the likely impact of an EPAC on the findings and conclusions of
clinical trials prior to their establishment. The appointment of an
EPAC has now become a knee jerk response in the design of large-
scale clinical trials, but actually warrants the same careful scientific
consideration as other aspects of the trial design. Thus the need for
formal endpoint adjudication may vary with the trial design, the
outcomes and the settings in which the particular trial is
conducted. Formal quantitative estimates of the likelihood of an
adjudication process influencing trial conclusions might also be
used to better understand the potential benefits of implementing
an EPAC. In addition, national and international regulatory
agencies could play a lead role in rationalizing the use of
adjudication processes by providing explicit advice based on a
clear understanding of what an EPAC can reasonably be expected
to contribute. Although the reassurance that the EPAC provided
to the users of the ADVANCE trial was no doubt of substantial
importance, there may be more cost-efficient ways of achieving
this goal.
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